# Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

> **NCT02405520** · PHASE1 · COMPLETED · sponsor: **Jun Zhang** · enrollment: 145 (actual)

## Conditions studied

- Condylomata Acuminata

## Interventions

- **BIOLOGICAL:** low dosage HPV Vaccine
- **BIOLOGICAL:** medium dosage HPV Vaccine
- **BIOLOGICAL:** high dosage HPV Vaccine
- **BIOLOGICAL:** Aluminium Adjuvant

## Key facts

- **NCT ID:** NCT02405520
- **Lead sponsor:** Jun Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-26
- **Primary completion:** 2019-06-05
- **Final completion:** 2022-05-20
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405520, "Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02405520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*